StreetInsider.com News Articles

MediciNova Phase 2 liver disease trial misses primary endpoints

Mon, 12 Oct 2026 06:02:49 -0400

MediciNova, Inc. (NASDAQ: MNOV) released results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) in patients with nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus, according to a shareholder letter from CEO Yuichi Iwaki.

The randomized, double-blind, placebo-controlled study enrolled 40 patients over a 24-week treatment period. The trial did not achieve statistical significance on its primary endpoints. Statistically significant improvements were observed in high-density lipoprotein cholesterol and HDL particle concentration compared with placebo, along with an early, statistically significant reduction in serum triglycerides. Reductions in serum triglycerides, liver fat, and body weight were also recorded

MediciNova CEO Provides Shareholder Update

Mon, 12 Oct 2026 06:00:00 -0400

LA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), today provides shareholders an update on key findings from the recent topline results of its Phase 2 clinical trial evaluating MN-001 for the treatment of nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus in the following letter from CEO Yuichi Iwaki, Ph.D.

To Fellow Shareholders,

We continue to advance our key programs to

MediciNova CEO Provides Shareholder Update

Mon, 12 Oct 2026 06:00:00 -0400

To Fellow Shareholders,

We continue to advance our key programs to

MediciNova to Participate in the Maxim Growth Summit

Tue, 06 Oct 2026 06:00:00 -0400

LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that management will participate in the Maxim Growth Summit taking place October 12-14, 2026, at the Hard Rock Hotel New York. Management will be available for one-on-one meetings with investors registered for the event.

Investors interested in scheduling a meeting with MediciNova management should contact their Maxim representative or visit here for more information.

About MediciNova

MediciNova to Participate in the Maxim Growth Summit

Tue, 06 Oct 2026 06:00:00 -0400

Investors interested in scheduling a meeting with MediciNova management should contact their Maxim representative or visit here for more information.

About MediciNova

Form SCHEDULE 13D/A MEDICINOVA INC Filed by: 3D Investment Partners Pte. Ltd.

Tue, 29 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260929/27123270.html

Form 4 MEDICINOVA INC For: Sep 25 Filed by: 3D Opportunity Master Fund

Tue, 29 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260929/27123267.html

H.C. Wainwright Reiterates Buy Rating on MediciNova (MNOV)

Tue, 29 Sep 2026 06:50:12 -0400

H.C. Wainwright analyst Lander Egana Gorrono reiterated a Buy rating and $10.00 price target on MediciNova (NASDAQ: MNOV).

The analyst commented: "This morning, MediciNova announced topline results from the Phase 2 NATG-202 study evaluating tipelukast (MN-001) for the treatment of hypertriglyceridemia (HTG) and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes (T2D). As a reminder, NATG-202 was a multi-center (U.S.), randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tipelukast in 40 T2D patients with HTG and NAFLD (NCT05464784). Participants (FibroScan score ≥ 248 dB/m, HbA1c >6.5 and ≤10% at screening, oral anti-diabetic therapy for ≥3 months, fasting

Form 8-K MEDICINOVA INC For: Sep 23

Mon, 28 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260928/27114490.html

MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

Mon, 28 Sep 2026 09:15:50 -0400

Investing.com -- MediciNova Inc (NASDAQ:MNOV) shares fell 14.7% in premarket trading Monday following mixed results from a Phase 2 clinical trial evaluating tipelukast (MN-001) for the treatment of nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus.

The company announced topline results from the MN-001-NATG-202 trial, which failed to meet statistical significance on its primary endpoints at Week 24. While the drug showed a statistically significant reduction in serum triglycerides at Week 4, this effect was not maintained at the study's conclusion.

The randomized, double-blind, placebo-controlled study enrolled 40 patients with

MediciNova reports mixed Phase 2 results for tipelukast in NAFLD

Mon, 28 Sep 2026 06:01:39 -0400

MediciNova, Inc. (NASDAQ: MNOV) announced topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes mellitus.

The randomized, double-blind, placebo-controlled study enrolled 40 patients over a 24-week treatment period. The trial met some but not all of its key endpoints.

Serum triglycerides declined by 26.05% in the MN-001 group at Week 4, compared with 11.54% in the placebo group, a difference that was statistically significant (p=0.015). At Week 24, the MN-001 group showed a 21.78% reduction versus 6.97% for placebo, but that difference was not statistically

MediciNova reports mixed Phase 2 results for tipelukast in NAFLD

Mon, 28 Sep 2026 06:01:39 -0400

The randomized, double-blind, placebo-controlled study enrolled 40 patients over a 24-week treatment period. The trial met some but not all of its key endpoints.

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

Mon, 28 Sep 2026 06:00:00 -0400

MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat

LA JOLLA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). In the MN-001 group,

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

Mon, 28 Sep 2026 06:00:00 -0400

MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat

MediciNova completes double-blind phase of ALS trial for MN-166

Thu, 24 Sep 2026 06:00:17 -0400

MediciNova, Inc. (NASDAQ: MNOV) announced the completion of the last patient, last visit in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast) as a treatment for Amyotrophic Lateral Sclerosis (ALS), according to a press release dated Sept. 24, 2026.

A total of 234 participants were randomized across two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment with MN-166 in an open-label extension phase. The last patient, last visit for the entire study is expected in March 2027.

MediciNova expects to report topline results from

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

Thu, 24 Sep 2026 06:00:00 -0400

LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of the last patient, last visit (LPLV) in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 participants were randomized to two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

Thu, 24 Sep 2026 06:00:00 -0400

Roth/MKM Starts MediciNova (MNOV) at Buy

Thu, 17 Sep 2026 02:51:46 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ: MNOV) with a Buy rating and a price target of $6.00.

The analyst comments: “We initiate coverage of MediciNova with a Buy rating and 12-month PT of $6. Our optimism is predicated upon unmet needs in amyotrophic lateral sclerosis (ALS) treatment, Ph1b/2a study of Ibudilast (MN-166) showing evidence of disease stabilization & survival benefits (p=0.2) and a fully enrolled Ph2b/3 study (data in 4Q26). Assuming positive results, MNOV could seek FDA approval in 2H27 and potentially launch the drug in 2H28. We estimate MN-166 achieving a peak risk unadjusted U.S. + EU5

Roth/MKM Starts MediciNova (MNOV) at Buy

Thu, 17 Sep 2026 02:51:46 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ: MNOV) with a Buy rating and a price target of $6.00.

MediciNova to Participate in Two Investor Conferences in September

Tue, 08 Sep 2026 06:00:00 -0400

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will participate in two investor conferences during September.

H.C. Wainwright 28^th Annual Global Investment Conference, September 14-16 at the Lotte New York Palace Hotel. Management will hold one-on-one meetings with investors during the conference. A virtual presentation will be available on demand

MediciNova to Participate in Two Investor Conferences in September

Tue, 08 Sep 2026 06:00:00 -0400

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will participate in two investor conferences during September.

H.C. Wainwright 28^th Annual Global Investment Conference, September 14-16 at the Lotte New York Palace Hotel. Management will hold one-on-one meetings with investors during the conference. A virtual presentation will be available on demand

Form 8-K MEDICINOVA INC For: Aug 17

Wed, 19 Aug 2026 07:30:00 -0400
si-local-file:///var/storage/secattach/20260819/26947260.html

Form 8-K MEDICINOVA INC For: Aug 17

Wed, 19 Aug 2026 07:30:00 -0400
si-local-file:///var/storage/secattach/20260819/26947260.html

Form 10-Q MEDICINOVA INC For: Jun 30

Thu, 13 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260813/26921865.html

Form 10-Q MEDICINOVA INC For: Jun 30

Thu, 13 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260813/26921865.html

StreetInsider.com News Articles

MediciNova Phase 2 liver disease trial misses primary endpoints

MediciNova CEO Provides Shareholder Update

MediciNova CEO Provides Shareholder Update

MediciNova to Participate in the Maxim Growth Summit

MediciNova to Participate in the Maxim Growth Summit

Form SCHEDULE 13D/A MEDICINOVA INC Filed by: 3D Investment Partners Pte. Ltd.

Form 4 MEDICINOVA INC For: Sep 25 Filed by: 3D Opportunity Master Fund

H.C. Wainwright Reiterates Buy Rating on MediciNova (MNOV)

Form 8-K MEDICINOVA INC For: Sep 23

MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

MediciNova reports mixed Phase 2 results for tipelukast in NAFLD

MediciNova reports mixed Phase 2 results for tipelukast in NAFLD

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova completes double-blind phase of ALS trial for MN-166

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

Roth/MKM Starts MediciNova (MNOV) at Buy

Roth/MKM Starts MediciNova (MNOV) at Buy

MediciNova to Participate in Two Investor Conferences in September

MediciNova to Participate in Two Investor Conferences in September

Form 8-K MEDICINOVA INC For: Aug 17

Form 8-K MEDICINOVA INC For: Aug 17

Form 10-Q MEDICINOVA INC For: Jun 30

Form 10-Q MEDICINOVA INC For: Jun 30